DOW

Dow

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Basic Materials

industry

Chemicals

Exchange

NYSE

County of HQ

United States

Next Earnings Date

04/23/26

Business Summary

Charles River operates as a contract research and preclinical services provider to pharmaceutical and biotechnology companies, embedding itself early in the drug development lifecycle. It generates cash by offering outsourced research models, laboratory services, and regulatory support that reduce time-to-market for clients. The moat is built on long-term client relationships, specialized scientific infrastructure, and regulatory expertise that create switching costs in a compliance-heavy industry. When operating efficiently, scale and repeat business drive margin leverage, but that leverage cuts both ways when utilization softens.

VALUATION

P/E

-

Market Cap ($M USD)

$28,072

Forward P/E

31.7

PEG

1.3

PRICE TO SALES

0.7

PRICE TO BOOK

1.8

EV / EBITDA

36.9

5-Year Average P/E

DIVIDEND

Yield

4.50%

Annual Payout

$1.40

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-12.90%

Financial Health & Profitability

Earnings Per Share

-$3.70

Next Year EPS Growth Estimate

$1.23

Next Year Revenue Growth Estimate

2.50%

Return on Equity (ROE)

-16.40%

Operating Margin

0.40%

Debt-to-Equity

1.2

Piotroski F-Score

3

Altman Z-Score

1.7

Return on Invested Capital (ROIC)

-5.50%%

Current Ratio

2

Quick Ratio

Gainseekers Quantitative Analysis

Summary

CRL screens as a conflicted deep value turnaround with material financial stress. A Forward P/E of 14.1 is not demanding on the surface, but the 3.4 PEG Forward signals weak growth relative to price, and the Altman Z-Score of 2.4 places the firm in the grey zone where balance sheet risk is not trivial. Profitability is clearly impaired with an Operating Margin of -4.60% and ROIC of -1.10%, while Return on Equity sits at just 2.50%, suggesting capital is not being deployed efficiently. The market is not obviously mispricing explosive growth here; instead, it appears to be cautiously discounting a challenged earnings profile with limited margin of safety.

AI Exposure / Tech Reliance

As a Diagnostics & Research company within Healthcare, CRL operates in a data-intensive, science-driven niche where AI integration into drug discovery, preclinical analytics, and lab automation is increasingly mission-critical. The sector’s structural push toward efficiency and predictive modeling could enhance long-term productivity, but execution risk remains high given current negative operating margins. Technological resilience will depend on whether CRL can convert innovation into margin expansion rather than incremental cost burden.

The Bull Case

A value or GARP investor could argue that the stock’s 14.1 Forward P/E paired with a Market Cap of $8,666M reflects a reset valuation after operational stress, creating asymmetric upside if margins normalize. The Piotroski F-Score of 6 indicates middling but not distressed fundamentals, suggesting the balance sheet and operating structure are not collapsing despite negative profitability metrics. A Current Ratio of 1.3 shows acceptable short-term liquidity, and a modest TTM Yield of 0.8 provides at least some capital return signal. With Price/Sales at 2.2 and Price/Book at 2.7, the multiple structure is not extreme for Healthcare, leaving room for re-rating if EPS stabilizes beyond the current EPS Next Year (Est.) of -$2.91.

The Bear Case

The bear case is far more straightforward: profitability is deteriorating fast, with Operating Margin at -4.60%, ROIC at -1.10%, and EPS Next Year (Est.) of -$2.91 despite current EPS of 26.8, implying a dramatic earnings compression. Debt/Equity of 10.00% introduces leverage risk in a period of negative operating performance, and the 3.4 PEG Forward suggests investors are overpaying relative to expected growth. Altman Z-Score of 2.4 keeps the company out of the safe zone, and Return on Equity of 2.50% is insufficient compensation for the risk profile. With Dividend Per Share USD listed as - and Payout Ratio -, shareholders lack income support while waiting for a turnaround.

Market Sentiment & Smart Money

Short Interest %

3.70%

Analyst Consensus

2.26

Average Analyst Price Target

$36.94

Institutional Ownership %

70.10%

1-Year Beta

0.87

Insider Buying % (6 Mo)

0.20%%

Distance to 52-Week High

91.30%%

Distance to 52-Week Low

191.20%%